Radiation Physics

PV QA 3 - Poster Viewing Q&A 3

TU_6_3176 - Dosimetric Performance of a New Ring-Gantry Linear Accelerator for IMRT and VMAT Prostate Plans

Tuesday, October 23
1:00 PM - 2:30 PM
Location: Innovation Hub, Exhibit Hall 3

Dosimetric Performance of a New Ring-Gantry Linear Accelerator for IMRT and VMAT Prostate Plans
P. T. Teo1, F. Li2, D. Rhoades2, Z. L. Shen2, S. Jang2, R. J. Lalonde1, D. E. Heron3, S. Huq1, and D. C. Ling1; 1Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Pittsburgh Cancer Institute, Pittsburgh, PA, 3UPMC Hillman Cancer Center, Pittsburgh, PA

Purpose/Objective(s): We aimed to evaluate dosimetric performance and delivery efficiency of a new ring-gantry linac characterized by a staggered dual-layer multi-leaf collimator (MLC). Performance of treatment plans generated using a cloud-based planning system is reported here for the first time. Using IMRT & VMAT prostate plans, we compared performance of the ring gantry linac with that of a C-arm based linac. We hypothesized that both IMRT and VMAT treatments on the new system would yield similar target coverage and dose conformity, albeit with differences in treatment time and organ-at-risk (OAR) sparing.

Materials/Methods: 10 prostate cancer patients previously planned using a treatment planning system (TPS) and treated with VMAT on a conventional C-arm linac (2300EX) at a dose rate of 300 MU/min were retrospectively re-planned for the new linac using a newer version of the TPS. Each plan was re-planned for IMRT (7 and 9 fields) and VMAT (2 and 3 arcs). Prescription dose for the target was standardized to 66.6 Gy. Plans were normalized to deliver 100% prescription dose to 95% of the target volume. Due to limitations in the current version of the ring gantry system, plans were generated using a single layer MLC (leaf width of 1 cm). Metrics of plan quality such as dose conformity, OAR sparing, and monitor units (MU) for new IMRT & VMAT plans were compared with those of the clinically delivered plans. Wilcoxon signed-rank test was used to compare differences in plan quality.

Results: Compared to the clinically delivered plans, rectum/bladder sparing and dose conformity were comparable for the new 9-field IMRT & VMAT (2- and 3-arc) plans, but were inferior for the 7-field IMRT plan (p <0.05). Both new IMRT plans achieved significantly better femoral head sparing than the delivered plans and the new VMAT plans (p <0.05). A significantly higher MU was required for all new plans (P < 0.05), to compensate for the wider leaf width. However, delivery time for the new VMAT plans is about 3 times shorter on the new system due to faster gantry and MLC motion. Table 1: Dosimetric comparison between clinically treated plans vs. plans for the ring-gantry linac
Clinically Delivered Plans for new ring-gantry linac
7-field IMRT 9-field IMRT 2-arc VMAT 3-arc VMAT
CI 1.02 ± 0.02 1.10 ± 0.05 1.06 ± 0.03 1.05 ± 0.03 1.04 ± 0.02
HI 1.05 ± 0.01 1.06 ± 0.01 1.05 ± 0.01 1.06 ± 0.01 1.05 ± 0.01
MU 666 ± 179 931 ± 216 948 ± 232 1123 ± 465 1151 ± 271
Rectum V70 (%) 33.3 ± 11.4 35.8 ± 14.9 31.5 ± 11.6 31.7 ± 10.1 33.1 ± 13.4
Bladder V70 (%) 32.2 ± 21.4 33.9 ± 20.8 28.8 ± 20.0 30.6 ± 18.4 31.1 ± 20.3
Left Femoral Head V30 (%) 19.1 ± 15.2 7.6 ± 10.4 9.7 ± 9.4 19.0 ± 14.3 17.9 ± 15.0
Right Femoral Head V30 (%) 18.3 ± 17.9 8.83 ± 15.5 4.5 ± 7.9 21.7 ± 11.9 16.0 ± 11.4

Conclusion: The 9-field IMRT and 2- and 3-arc VMAT prostate plans generated for the new ring-gantry linac offer dose coverage and OAR sparing that is comparable to the VMAT plans delivered on the conventional linac. When comparing ring-gantry IMRT and VMAT plans, the 9-field IMRT plans achieved better OAR sparing while maintaining similar dose coverage.

Author Disclosure: P.T. Teo: None. F. Li: None. D. Rhoades: None. Z.L. Shen: None. S. Jang: Travel Expenses; UPMC. R.J. Lalonde: None. D.E. Heron: No personal compensation; Accuray Exchange in Radiation Oncology. Partnership; Cancer Treatment Services International. Vice Chairman of Clinical Affairs; University of Pittsburgh School of Medicine. Director of Radiation Services; UPMC CancerCenter. S. Huq: None.

Peng (Troy) Teo, PhD

Presentation(s):

Send Email for Peng (Troy) Teo


Assets

TU_6_3176 - Dosimetric Performance of a New Ring-Gantry Linear Accelerator for IMRT and VMAT Prostate Plans



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Dosimetric Performance of a New Ring-Gantry Linear Accelerator for IMRT and VMAT Prostate Plans